Journal of Cutaneous Medicine and Surgery

, Volume 8, Issue 5, pp 310–320 | Cite as

Patient Satisfaction with Psoriasis Therapies: An Update and Introduction to Biologic Therapy

Basic/Clinical Science

Abstract

Background

Psoriasis is a chronic, immune-mediated skin condition that often requires lifelong treatment. Many patients report dissatisfaction with traditional nonbiologic therapies because they are ineffective for their psoriasis, are associated with side effects, or impact negatively on quality of life.

Objectives

The aim of this article is to review the effect on patient quality of life of traditional nonbiologic psoriasis therapies and to discuss the impact of biologic psoriasis therapies on patient satisfaction.

Methods

A review of the literature is presented.

Results

Traditional nonbiologic psoriasis therapies can negatively impact quality of life due to a variety of factors including inconvenience and toxicity. Biologic agents have been developed that target the immunopathogenesis of psoriasis. Based on favorable efficacy and safety results in clinical trials, some of these agents are now approved for clinical use. Evidence suggests that patients receiving biologic therapies experience significant improvements in health-related quality of life.

Conclusion

Biologic agents offer new hope for patients with psoriasis that their chronic condition can be controlled in a manner that improves their quality of life and may lead to high levels of satisfaction with their treatment.

Sommaire

Antécédents

Le psoriasis est une affection cutanée chronique et à médiation immunologique qui nécessite souvent un traitement la vie longue. Un grand nombre de patients sont insatisfaits des traitements traditionnels non biologiques en raison de leur inefficacité contre le psoriasis, des effets secondaires ou de leur conséquences négatives sur la qualité de vie.

Objectifs

L’objectif du présent article est de passer en revue l’effet des traitements traditionnels non biologiques sur la qualité de vie des patients atteints de psoriasis et de discuter l’impact des traitements biologiques sur la satisfaction des patients.

Méthodes

Une révision des articles et des rapports publiés est présentée.

Résultats

Les traitements traditionnels non biologiques du psoriasis ont un impact négatif sur la qualité de vie des personnes affectées pour plusieurs raisons, notamment la toxicité et l’incommodité. Des agents biologiques qui s’attaquent à l’immunopathogenèse du psoriasis ont été mis au point. À la suite des résultats favorables quant à leur efficacité et à leur innocuité dans les essais cliniques, certains de ces agents ont été approuvés dans les traitements cliniques. Les symptômes suggèrent que les patients ayant reçu un traitement biologique présentent des améliorations considérables à la qualité de vie reliée à la santé.

Conclusion

Les agents biologiques offrent aux patients souffrant de psoriasis un nouvel espoir que leur condition chronique pourra être maîtrisée de façon à améliorer leur qualité de vie et qu’ils pourront être grandement satisfaits de leur traitement.

References

  1. 1.
    Stern, RS, Nijsten, T, Feldman, SR,  et al. 2004Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfactionJ Investig Dermatol Symp Proc9136139CrossRefPubMedGoogle Scholar
  2. 2.
    Camisa, C. 2000Psoriasis: a clinical update on diagnosis and new therapiesCleve Clin J Med67105113, 117PubMedGoogle Scholar
  3. 3.
    Lebwohl, M. 2003PsoriasisLancet.36111971204CrossRefPubMedGoogle Scholar
  4. 4.
    Farber, EM, Nail, L. 1992Nail psoriasisCutis.50174178PubMedGoogle Scholar
  5. 5.
    Gottlieb, AB. 1998PsoriasisDis Manage Clin Outcomes1195202CrossRefGoogle Scholar
  6. 6.
    Lebwohl, M, Feldman, SR, Walther, R,  et al. 2001Clinical management of psoriasis: principles and practiceCutis67115PubMedGoogle Scholar
  7. 7.
    Korte, J, Sprangers, MA, Mombers, FM,  et al. 2004Quality of life in patients with psoriasis: a systematic literature reviewJ Investig Dermatol Symp Proc9140147CrossRefPubMedGoogle Scholar
  8. 8.
    Rapp, SR, Feldman, SR, Exum, ML,  et al. 1999Psoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol41401407PubMedGoogle Scholar
  9. 9.
    Richards, HL, Fortune, DG, Main, CJ,  et al. 2003Stigmatization and psoriasisBr J Dermatol149209211CrossRefPubMedGoogle Scholar
  10. 10.
    Gupta, MA, Gupta, AK. 2003Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and managementAm J Clin Dermatol4833842PubMedGoogle Scholar
  11. 11.
    Heydendael, VM, Borgie, CA, Spuls, PI,  et al. 2004The burden of psoriasis is not determined by disease severity onlyJ Investig Dermatol Symp Proc9131135CrossRefPubMedGoogle Scholar
  12. 12.
    Sampogna, F, Sera, F, Abeni, D. 2004Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysisJ Invest Dermatol122602607CrossRefPubMedGoogle Scholar
  13. 13.
    Tristani–Firouzi, P, Krueger, GG. 1998Efficacy and safety of treatment modalities for psoriasisCutis611121PubMedGoogle Scholar
  14. 14.
    Krueger, G, Koo, J, Lebwohl, M,  et al. 2001The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol137280284PubMedGoogle Scholar
  15. 15.
    Salonen SH, the EUROPSO Patient Survey Study Group. The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Poster presented at Spring Symposium of the European Academy of Dermatology and Venereology, 27 February–1 March 2003, MaltaGoogle Scholar
  16. 16.
    Sterry, W, Barker, J, Boehncke, WH,  et al. 2004Biological therapies in the systemic management of psoriasis: International Consensus ConferenceBr J Dermatol151317CrossRefPubMedGoogle Scholar
  17. 17.
    Peters, BP, Weissman, FG, Gill, MA. 2000.Am J Health Syst Pharm57645959PubMedGoogle Scholar
  18. 18.
    Menter, MA, Abramovits, W. 1999Rational, sequential and combination regimens in the treatment of psoriasisDermatol Ther118895Google Scholar
  19. 19.
    Mrowietz, U, Christophers, E, Altmeyer, P. 1999Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus ConferenceBr J Dermatol141424429CrossRefPubMedGoogle Scholar
  20. 20.
    Koo, JY. 1999Current consensus and update on psoriasis therapy: a perspective from the U.SJ Dermatol26723733PubMedGoogle Scholar
  21. 21.
    Kerkhof, PC. 2001Therapeutic strategies: rotational therapy and combinationsClin Exp Dermatol26356361CrossRefPubMedGoogle Scholar
  22. 22.
    Zaghloul, SS, Goodfield, MJ. 2004Objective assessment of compliance with psoriasis treatmentArch Dermatol140408414CrossRefPubMedGoogle Scholar
  23. 23.
    Stern, RS. 2003A promising step forward in psoriasis therapyJAMA29031333135CrossRefPubMedGoogle Scholar
  24. 24.
    Krutmann, J. 1999The treatment of psoriasis: UVBDermatol Ther113236Google Scholar
  25. 25.
    Lebwohl, M. 2002New developments in the treatment of psoriasisArch Dermatol138686688CrossRefPubMedGoogle Scholar
  26. 26.
    Ho, VC. 2004The use of ciclosporin in psoriasis: a clinical reviewBr J Dermatol150110CrossRefPubMedGoogle Scholar
  27. 27.
    Heydendael, VM, Spuls, PI, Opmeer, BC,  et al. 2003Methotrexate versus cyclosporine in moderate-to severe chronic plaque psoriasisN Engl J Med349658665CrossRefPubMedGoogle Scholar
  28. 28.
    Neoral® soft gelatin capsules (cyclosporin capsules, USP) modified; Neoral® oral solution (cyclosporin oral solution, USP) modified [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation, August 2002Google Scholar
  29. 29.
    Griffiths, CE, Clark, CM, Chalmers, RJ,  et al. 2000A systematic review of treatments for severe psoriasisHealth Technol Assess41125PubMedGoogle Scholar
  30. 30.
    Linden, KG, Wienstein, GD. 1999Use of methotrexate in psoriasisDermatol Ther115259Google Scholar
  31. 31.
    Lowe, NJ, Wieder, JM, Rosenbach, A,  et al. 1996Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structureJ Am Acad Dermatol35710719CrossRefPubMedGoogle Scholar
  32. 32.
    Markham, T, Watson, A, Rogers, S. 2002Adverse effects with long-term cyclosporin for severe psoriasisClin Exp Dermatol27111114CrossRefPubMedGoogle Scholar
  33. 33.
    Zachariae, H, Hansen, HE, Kragballe, K,  et al. 1992Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimensJ Am Acad Dermatol26415419PubMedCrossRefGoogle Scholar
  34. 34.
    Zachariae, H. 1999Renal toxicity of long-term cyclosporinScand J Rheumatol286568CrossRefPubMedGoogle Scholar
  35. 35.
    Griffiths, CE, Dubertret, L, Ellis, CN,  et al. 2004Ciclosporin in psoriasis clinical practice: an international consensus statementBr J Dermatol1501123CrossRefPubMedGoogle Scholar
  36. 36.
    Naldi, L, Svensson, A, Diepgen, T,  et al. 2003Randomized clinical trials for psoriasis 1977–2000: the EDEN surveyJ Invest Dermatol120738741CrossRefPubMedGoogle Scholar
  37. 37.
    Weinstein, GD, White, GM. 1993An approach to the treatment of moderate to severe psoriasis with rotational therapyJ Am Acad Dermatol28454459PubMedCrossRefGoogle Scholar
  38. 38.
    Chalmers, RJ, Griffiths, CE. 2003Resetting the research agenda for psoriasisJ Invest Dermatol120ixCrossRefPubMedGoogle Scholar
  39. 39.
    Ben–Arye, E, Ziv, M, Frenkel, M,  et al. 2003Complementary medicine and psoriasis: linking the patient’s outlook with evidence-based medicineDermatology207302307CrossRefPubMedGoogle Scholar
  40. 40.
    Finlay, AY. 2001Psoriasis from the patient’s point of viewArch Dermatol137352353PubMedGoogle Scholar
  41. 41.
    National Psoriasis Foundation. NPF Benchmark survey on psoriasis and psoriatic arthritis. Available at http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf. Accessed 11/11/03
  42. 42.
    Richards, HL, Fortune, DG, O’Sullivan, TM,  et al. 1999Patients with psoriasis and their compliance with medicationJ Am Acad Dermatol41581583PubMedGoogle Scholar
  43. 43.
    Hermansen, SE, Helland, CA, Finlay, AY. 2002Patients’ and doctors’ assessment of skin disease handicapClin Exp Dermatol27249250CrossRefPubMedGoogle Scholar
  44. 44.
    Ersser, SJ, Surridge, H, Wiles, A. 2002What criteria do patients use when judging the effectiveness of psoriasis management?J Eval Clin Pract8367376CrossRefPubMedGoogle Scholar
  45. 45.
    Krueger, JG. 2002The immunologic basis for the treatment of psoriasis with new biologic agentsJ Am Acad Dermatol46123PubMedGoogle Scholar
  46. 46.
    Weinberg, JM. 2003An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasisClin Ther2524872505CrossRefPubMedGoogle Scholar
  47. 47.
    Biogen Idee. Amevive® (alefacept) prescribing information. Available at http://www.amevive.com. Accessed 11/3/04. Aug 2004.
  48. 48.
    Lebwohl, M, Christophers, E, Langley, R,  et al. 2003An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol139719727CrossRefPubMedGoogle Scholar
  49. 49.
    Krueger, GG, Papp, KA, Stough, DB,  et al. 2002A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol47821833CrossRefPubMedGoogle Scholar
  50. 50.
    Gordon, KB, Langley, RG. 2003Remittive effects of intramuscular alefacept in psoriasisJ Drugs Dermatol2624628PubMedGoogle Scholar
  51. 51.
    Menter, A, Gather, JC. 2004Long-term use of intravenous alefacept: safety and off-treatment responses in patients who have received four or more courses of therapy [abstract P588]J Am Acad Dermatol50P151Google Scholar
  52. 52.
    Gordon, KB, Papp, KA, Hamilton, TK,  et al. 2003Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialJAMA29030733080PubMedGoogle Scholar
  53. 53.
    Lebwohl, M, Tyring, SK, Hamilton, TK,  et al. 2003A novel targeted T-cell modulator, efalizumab, for plaque psoriasisN Engl J Med34920042013CrossRefPubMedGoogle Scholar
  54. 54.
    Menter A, Toth D, Glazer S, et al. Efficacy and safety of 24-week continuous efalizumab therapy in patients with moderate to severe plaque psoriasis. Poster presented at Meeting of the American Association of Dermatology Academy, 25–29 July 2003, Chicago, ILGoogle Scholar
  55. 55.
    Gottlieb AB, Gordon KB, Caro I, et al. Long-term efalizumab therapy safely maintains psoriasis area and severity index improvement: Preliminary results from an open-label trial. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DCGoogle Scholar
  56. 56.
    Immunex Corporation. Enbrel® (etanercept) prescribing information. Available at http://www.wyeth.com/content/ShowLabeling.asp?id= 101. Accessed 11/3/04.Oct 2004
  57. 57.
    Leonardi, CL, Powers, JL, Matheson, RT,  et al. 2003Etanercept as monotherapy in patients with psoriasisN Engl J Med34920142022CrossRefPubMedGoogle Scholar
  58. 58.
    Centocor Inc. Remicade® (infliximab) prescribing information. Available at http://www.remicade.com/pdf/IN04560.pdf. Accessed Oct 2004
  59. 59.
    Gottlieb, AB, Chaudhari, U, Mulcahy, LD,  et al. 2003Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasisJ Am Acad Dermatol48829835CrossRefPubMedGoogle Scholar
  60. 60.
    Chaudhari, U, Romano, P, Mulcahy, LD,  et al. 2001Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialLancet35718421847CrossRefPubMedGoogle Scholar
  61. 61.
    Gottlieb AB, Evans R, Patel K, Matheson R. Infliximab improves signs of plaque psoriasis in patients with psoriatic arthritis. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology 6–11 February 2004, Washington, DC, poster 612Google Scholar
  62. 62.
    Abbott Laboratories. Humira® (adalimumab) prescribing information. Available at http://www.rxabbott.com/pdf/humira.pdf. Accessed 11/3/04. July 2004
  63. 63.
    Gottlieb AB, Gordon KB, Caro I, et al. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DCGoogle Scholar
  64. 64.
    Wallace K, Heffeman M, Hamlin R, et al. Results of the DLQI dermatology-specific quality of life measure in moderate to severe plaques psoriasis patients receiving 24 weeks of adalimumab therapy. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February, 2004, Washington, DCGoogle Scholar
  65. 65.
    Wallace K, Miller B, Heffeman M, et al. Results of the SF-36 general health status measure in moderate to severe plaques psoriasis patients treated with adalimumab for 24 weeks. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology 6–11 February 2004, Washington, DCGoogle Scholar
  66. 66.
    Anonymous2003Efalizumab (Raptiva) for treatment of psoriasisMed Lett Drugs Ther459798Google Scholar
  67. 67.
    Krueger, GG, Lebwohl, M, Wang, A,  et al. 2004Continuance on etanercept after early incomplete response in patients with psoriasis [abstract P546]J Am Acad Dermatol50P141Google Scholar
  68. 68.
    Anonymous2004Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002–2003Morb Mortal Wkly Rep53683686Google Scholar
  69. 69.
    Mohan, N, Edwards, ET, Cupps, TR,  et al. 2001Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritidesArthritis Rheum4428622869CrossRefPubMedGoogle Scholar
  70. 70.
    Kwon, HJ, Cote, TR, Cuffe, MS,  et al. 2003Case reports of heart failure after therapy with a tumor necrosis factor antagonistAnn Intern Med138807811PubMedGoogle Scholar
  71. 71.
    Baert, F, Noman, M, Vermeire, S,  et al. 2003Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med348601608CrossRefPubMedGoogle Scholar
  72. 72.
    Gordon, KB, Koo, JYM, Feldman, SR,  et al. 2002Definitions of measures of effect duration for psoriasis treatmentsPsoriasis Forum815Google Scholar
  73. 73.
    Boyd, AS, Menter, A. 1989Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patientsJ Am Acad Dermatol21985991CrossRefPubMedGoogle Scholar
  74. 74.
    Cacoub, P, Artru, L, Canesi, M,  et al. 1988Life-threatening psoriasis relapse on withdrawal of cyclosporinLancet2219220CrossRefPubMedGoogle Scholar
  75. 75.
    Heidenheim, M, Oxholm, A, da Cunha, BF. 1990Generalized pustular psoriasis in relation to withdrawal of cyclosporin ABr J Dermatol122719PubMedGoogle Scholar
  76. 76.
    Mahendran, R, Grech, C. 1998Generalized pustular psoriasis following a short course of cyclosporin (Neoral)Br J Dermatol139934CrossRefPubMedGoogle Scholar
  77. 77.
    Georgala, S, Koumantaki, E, Rallis, E,  et al. 2000Generalized pustular psoriasis developing during withdrawal of short-term cyclosporin therapyBr J Dermatol14210571058CrossRefPubMedGoogle Scholar
  78. 78.
    Kamarashev, J, Lor, P, Forster, A,  et al. 2002Generalised pustular psoriasis induced by cyclosporin A withdrawal responding to the tumour necrosis factor alpha inhibitor etanerceptDermatology205213216CrossRefPubMedGoogle Scholar
  79. 79.
    Raptiva™ (efalizumab) package insert. South San Francisco, CA, Genentech, Inc., October 2003Google Scholar
  80. 80.
    Menter A, Kardatzke D, Rundle AC, et al. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presented at 10th International Psoriasis Symposium, 10-13 June 2004, Toronto, CanadaGoogle Scholar
  81. 81.
    Yazici, Y, Erkan, D, Paget, SA. 2003Monitoring by rheumatolegists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse eventsArthritis Rheum4827692772CrossRefPubMedGoogle Scholar
  82. 82.
    Finlay, AY, Khan, GK. 1994Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical useClin Exp Dermatol19210216PubMedGoogle Scholar
  83. 83.
    Lewis, V, Finlay, AY. 200410 years experience of the Dermatology Life Quality Index (DLQI)J Investig Dermatol Symp Proc9169180CrossRefPubMedGoogle Scholar
  84. 84.
    Weisman, S, Pollack, CR, Gottschalk, RW. 2003Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasisJ Dermatolog Treat14158165CrossRefPubMedGoogle Scholar
  85. 85.
    Hongbo, Y, Thomas, CL, Harrison, MA et al. (2003) “Translation- The Science of Quality of Life into Practice: what do Dermatology Life Quality Index (QLDL) Scores mean? “ J Invest Dermatol (in press)Google Scholar
  86. 86.
    Finlay, AY. 1998Quality of life assessments in dermatologySemin Cutan Med Surg17291296PubMedGoogle Scholar
  87. 87.
    Salek, MS, Finlay, AY. 2003Quality of life in patients with severe psoraisis receiving cyclosporin: a multicentre studyJ Appl Ther Res4310Google Scholar
  88. 88.
    Ellis, CN, Mordin, MM, Adler, EY. 2003Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trialAm J Clin Dermatol4131139PubMedGoogle Scholar
  89. 89.
    Feldman, SR, Menter, A, Koo, JY. 2004Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasisBr J Dermatol150317326CrossRefPubMedGoogle Scholar
  90. 90.
    Finlay, AY, Salek, MS, Haney, J,  et al. 2003Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasisDermatology206307315CrossRefPubMedGoogle Scholar
  91. 91.
    Menter, A, Kosinski, M, Bresnahan, BW,  et al. 2004Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasisJ Drugs Dermatol32738PubMedGoogle Scholar
  92. 92.
    Stone, SP, Caro, I. 2004Elfalizumab—A new T-cell modulator to improve psoriasis managementNorth Am Pharmacother.15Google Scholar
  93. 93.
    Krueger, GG, Woolley, JM, Zitnik, R. 2004The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis [Abstract P603]J Am Acad Dermatol50P155CrossRefGoogle Scholar
  94. 94.
    Feldman, SR, Kimball, A, Woolley, JM,  et al. 2004Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasisJ Am Acad Dermatol50P155CrossRefGoogle Scholar
  95. 95.
    Goffe B, Gottlieb A, Lebwohl M, et al. Etanercept in patients with psoriatic arthritis: sustained improvement in skin and joint disease. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology, 6–11 February 2004, Washington, DC, poster 210Google Scholar
  96. 96.
    Weinberg, JM, Saini, R. 2003Biologic therapy for psoriasis: the tumor necrosis factor inhibitors—infliximab and etanerceptCutis712529PubMedGoogle Scholar
  97. 97.
    Weinberg, JM, Tutrone, WD. 2003Biologic therapy for psoriasis: the T-cell-targeted therapies—efalizumab and alefaceptCutis714145PubMedGoogle Scholar
  98. 98.
    Scheinfeld, N. 2003Adalimumab (Humira): a reviewJ Drugs Dermatol2375377PubMedGoogle Scholar
  99. 99.
    Feldman SR, Bala M, Menter A, et al. The quality of life of patients with severe psoriasis treated with infliximab [abstract P7]. J Am Acad Dermatol 2004; 50:P2Google Scholar
  100. 100.
    Papp KA, Gulliver WP, Monroe E, et al. Retreatment of moderate to severe psoriasis with subcutaneous efalizumab (anti-CD11a): results from an open-label study. Poster presented at 60th Annual Meeting of the American Academy of Dermatology, New Orleans, Louisiana, 22–27 February 2002, poster 27Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Department of Dermatology Wales College of Medicine, Cardiff UniversityCardiffU.K.
  2. 2.Department of Dermatology Wales College of Medicine, Health ParkCardiffU.K.

Personalised recommendations